A Study Evaluating the Efficacy and Safety of CKD-314 (Nafabelltan) in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia

NCT04623021 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

104

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19

Interventions

DRUG: Nafamostat Mesilate

Sponsor

Chong Kun Dang Pharmaceutical